Clinical Guidelines for the Management of IBD
No abstract Full Text Link: https://libkey.io/34534537?utm_source=ibdwatch
Read MoreCategory: Treatment Strategies
Top Treatment Strategies
Management of Biologic Therapy Before Elective Inflammatory Bowel Disease Surgeries
Hanson et al. IBD Journal 2019
Treatment De-Escalation in patients with Inflammatory Bowel Disease
Rubin et al. Gastro & Hep 2019
The Treatment of Inflammatory Bowel Disease Patients with a History of Malignancy
Lin et al. IBD Journal 2019
Efficacy of Medical Therapies for Fisutalizing Crohn's Disease: Systemic Review and Meta-Analysis
Lee et al. CGH 2018
VARSITY: Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Sands et al. NEJM 2019
TAXIT: Trough Concentrations of Infliximab Guide Dosing for Patients with Inflammatory Bowel Disease
Casteele et al. Gastroenterology 2015
Inpatient Management of IBD Related Complications
Kaur et al. CGH 2020
The Surgical Management of IBD
Lightner et al. Current Problems in Surgery 2017
Recent Treatment Strategies
AGA publishes practice update for management of colorectal dysplasia in IBD
The American Gastroenterological Association published a conceptual model and clinical practice update for the prevention, detection and management of colorectal dysplasia in patients with inflammatory bowel disease. “Not long...
Read MoreCombination of vedolizumab and immunomodulators in Ulcerative Colitis
No abstract Full Text Link: https://libkey.io/34519096?utm_source=ibdwatch
Read MoreIs Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data
As a plethora of data emerges on therapeutic drug monitoring (TDM) of biologics in inflammatory bowel disease, guidance on its application is needed. In this literature review and consensus statement, the authors recommend...
Read MoreDynamic properties of the intestinal ecosystem call for combination therapies, targeting inflammation and microbiota, in ulcerative colitis
CONCLUSIONS: Our observations strongly suggest that inflammation suppression should be combined with microbiota management where possible to improve the efficacy of UC treatment. Full Text Link:...
Read MoreReal-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
CONCLUSIONS: Tofacitinib is a promising therapeutic agent for the induction and maintenance therapy in UC. Baseline UCEIS may predict its therapeutic effects. Full Text Link:...
Read MoreAGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review
Improvements in disease management, as well as endoscopic technology and quality, have dramatically changed the way in which we conceptualize and manage inflammatory bowel disease-related dysplasia over the past 20 years. Based...
Read MoreWhat's New in the Postoperative Management of Crohn's Disease?
Patients with Crohn’s disease (CD) often require surgical resection due to complications, such as strictures and abscesses, or disease refractory to medical therapy. To understand the evolving management of patients with...
Read MoreSuccess of Cyclosporin and Tofacitinib Combination Therapy in a Patient With Severe Steroid-refractory Ulcerative Colitis
At present, the conventional therapies for acute severe ulcerative colitis (ASUC) mainly include corticosteroids, cyclosporin, and biological agents. However, the treatment of patients with severe steroid-refractory ulcerative...
Read MoreA Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease
Therapeutic drug monitoring (TDM) of biologics is a rapidly evolving field. We aimed to provide a consensus statement regarding the clinical utility of TDM for biologics in inflammatory bowel disease (IBD). A modified Delphi...
Read More